Wednesday, February 1, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Pathogens

Patients with Alpha and Beta COVID-19 Variants Less Likely to Be Asymptomatic, Despite No Increase in Viral Load

by Global Biodefense Staff
June 23, 2021
Patients with Alpha and Beta COVID-19 Variants Less Likely to Be Asymptomatic, Despite No Increase in Viral Load

Credit: NIAID

Although two SARS-CoV-2 variants are associated with higher transmission, patients with these variants show no evidence of higher viral loads in their upper respiratory tracts compared to the control group, a Johns Hopkins School of Medicine study found.

This study was performed at Dr. Heba Mostafa’s research laboratory, which has been performing large scale whole genome sequencing of SARS-CoV-2 for the State of Maryland and contributing data to the national publicly available surveillance figures.

The researchers investigated B.1.1.7 (Alpha), the variant first identified in the UK, and B.1.351 (Beta), first identified in South Africa, to evaluate if patients showed higher viral loads, and consequently increased shedding and transmissibility.

Variants were identified using whole genome sequencing. Researchers used a large cohort of samples to show that the Alpha variant constituted 75% of the circulating viruses by April 2021. The researchers compared 134 variant samples to 126 control samples and with access to the patients’ clinical information, were able to correlate the genomics data with the clinical disease and outcomes. All samples underwent additional testing to determine their viral load. The information was associated with the stage of the disease by looking at the days after the start of symptoms which added clarity in comparing viral shedding between groups.

“The reason why these variants show higher transmissibility is not yet clear,” said Adannaya Amadi, lead author on the study. “However, our findings did show that the patients infected with these variants are less likely to be asymptomatic compared to the control group. Although those infected with the variants were not at higher risk for death or intensive care admission, they were more likely to be hospitalized.”

The research is being presented this week at the World Microbe Forum online from June 20-24 live from Baltimore, Maryland.

Tags: Editor PickEpidemiologyGenomicsSARS-CoV-2Transmission Dynamics

Related Posts

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions
Pathogens

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
The device appears smaller than a playing card, transparent, with visible channels branching off.
Medical Countermeasures

How Organ-on-a-chip Models Could Grease the Drug Development Pipeline

January 10, 2023
New Virus Discovered in Swiss Ticks
Biosurveillance

New Virus Discovered in Swiss Ticks

December 7, 2022
Load More

Latest News

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023
Biodefense Headlines – 17 January 2023

Biodefense Headlines – 17 January 2023

January 17, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC